Mr. Hodges was the founder and President of Metrics, Inc. Since founding Metrics in 1994, Hodges oversaw its transition from a start-up analytical laboratory with four employees to one of the Southeast’s premier pharmaceutical development laboratories with more than 350 employees. Throughout his tenure, Metrics experienced double-digit annual revenue growth. Metrics, Inc. was sold in 2012 to the Mayne Pharma Group, Ltd. of Melbourne, Australia. Prior to starting Metrics, Hodges worked for 11 years at Burroughs Wellcome Co. (which eventually became part of GlaxoSmithKline) in the development and validation of analytical methods. Since the sale of Metrics, Mr. Hodges has participated in several startup technology companies where he participates as a board chairman or LLC manager, including Chesson Laboratory Associates, XComP, Inc., and Nano Ventures, LLC. He is also a manager in Kaio Therapy, LLC, an immuno-oncology company where he helps lead their technical development. Hodges holds BS and MS degrees in chemistry and analytical chemistry from East Carolina University.
Before joining Perfusio, Peter Geiger served as Chief Financial Officer at DSM Pharmaceuticals, a contract pharmaceutical manufacturing company producing $2 billion worth of consumer products annually. Mr. Geiger brings to Perfusio significant financial leadership in health services start-ups, including serving as Managing General Partner of Geiger Investments Ltd., where he applies his expertise in company valuation to generate above-market returns for partners. In addition to an undergraduate degree in Behavioral Neuroscience from Lehigh University, Mr. Geiger graduated with honors from the Wharton School of Business at the University of Pennsylvania with an MBA in finance and strategic management.
Chief Science and Technical Officer and Co-Founder
A highly regarded optical physicist, Dr. Chen began creating Perfusio’s revolutionary technology in 2008. With expertise in imaging algorithm and visualization, Dr. Chen was one of the first to recognize the enormous clinical potential for real-time analysis of perfusion and blood flow. He developed the software that powers the company’s Complex Angiography and Perfusion Analysis (CAPA) platform and is co-inventor of its Multi-Spectral Physiologic Visualization (MSPV) technology. His leadership was critical for IP strategy and the patent application process and will lead the company to future applications, designs, and IP expansions. Dr. Chen earned his doctorate in Biomedical Physics from East Carolina University (ECU), which led to a significant career in optical imaging of turbid biological medium and publication of numerous papers in peer-reviewed scientific journals. After serving in ECU’s Physics and Engineering Departments, he is now an adjunct associate professor there. Dr. Chen is a member of the National Academy of Inventors and currently holds six patents, with more than 30 additional applications under review in the U.S. and internationally.
Mr. Alvarez has enjoyed a distinguished career and brings expertise in engineering operations and leadership in Medical Device product and service development for patients and physicians in multiple healthcare specialties. Prior to joining Perfusio, he was Senior Director of Engineering Operations and Quality at BIONIK, Inc., a global rehabilitation robotics manufacturer with data-driven robotic-assisted therapy solutions for patients with neurological impairments. Before that, he spent more than a decade steeped in Olympus Surgical Technologies America, where he managed cross-functional engineering teams and led operations and value stream initiatives for products in urology, gynecology, ENT, and general surgery markets. He is skilled in ISO 13485 and 21CFR820 certification and standards, quality management systems, design controls, lean manufacturing techniques, and organization development. He has an MBA from Kettering University with an undergraduate degree in biomedical/biomechanics engineering from the University of Rochester.